BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Cantor Fitzgerald
Chinese Patent Office
Federal Trade Commission
Moodys
QuintilesIMS
Julphar
Dow
Covington

Generated: January 19, 2018

DrugPatentWatch Database Preview

ZOLINZA Drug Profile

« Back to Dashboard

Which patents cover Zolinza, and what generic alternatives are available?

Zolinza is a drug marketed by Merck and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and thirty-one patent family members in thirty-five countries.

The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.
Drug patent expirations by year for ZOLINZA
Pharmacology for ZOLINZA

US Patents and Regulatory Information for ZOLINZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ZOLINZA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,288,440 Formulations of suberoylanilide hydroxamic acid and methods for producing same ➤ Subscribe
7,148,257 Methods of treating mesothelioma with suberoylanilide hydroxamic acid ➤ Subscribe
7,375,137 Methods of treating cancer with HDAC inhibitors ➤ Subscribe
7,847,122 Polymorphs of suberoylanilide hydroxamic acid ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ZOLINZA

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Deloitte
QuintilesIMS
Boehringer Ingelheim
Covington
UBS
Daiichi Sankyo
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot